FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028477515> ?p ?o ?g. }

• W3028477515 endingPage "245" @default.
• W3028477515 startingPage "236" @default.
• W3028477515 abstract "To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment.A prospective cohort, multicenter study on HIV-positive patients starting treatment with at least one PI.Ten departments of infectious diseases in Northern Italy.A total of 1207 patients who started PI therapy in September 1997 and were consecutively observed up to April 1999.Adverse reactions following initiation of PI therapy, and time to therapy discontinuation due to AE.During the study period, 35.9% patients presented adverse reactions of any grade, whereas 9.7% presented at least one serious AE. After 12 months of treatment, the percentage of patients who had interrupted treatment was 36% of ritonavir-treated patients, 14.2% of those treated with indinavir, 13.6% of ritonavir-saquinavir hard gel capsules (HGC)-treated patients, and 8.5% and 2.1%, respectively, for those treated with nelfinavir and saquinavir HGC. Women and patients with hepatitis experienced a significantly greater number of adverse events compared with other categories. Gastrointestinal events were more frequently observed in patients treated with either ritonavir alone or in combination with saquinavir HGC, as well as in patients receiving nelfinavir, although in this group serious events were rare. Here again, neurologic, metabolic, and hepatic toxicity occurred more frequently in ritonavir and ritonavir-saquinavir HGC treated patients. Allergic reactions were more often observed in patients receiving nelfinavir. Indinavir-treated patients presented the highest incidence of renal toxicity.Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment. Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting." @default.
• W3028477515 created "2020-05-29" @default.
• W3028477515 creator A5004101623 @default.
• W3028477515 creator A5011886669 @default.
• W3028477515 creator A5018523534 @default.
• W3028477515 creator A5019250260 @default.
• W3028477515 creator A5028933821 @default.
• W3028477515 creator A5036157453 @default.
• W3028477515 creator A5042498674 @default.
• W3028477515 creator A5047705773 @default.
• W3028477515 creator A5048761597 @default.
• W3028477515 creator A5057786657 @default.
• W3028477515 creator A5058012553 @default.
• W3028477515 creator A5075730095 @default.
• W3028477515 creator A5080933580 @default.
• W3028477515 creator A5083320502 @default.
• W3028477515 creator A5089321624 @default.
• W3028477515 date "2000-03-01" @default.
• W3028477515 modified "2023-10-18" @default.
• W3028477515 title "Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study" @default.
• W3028477515 cites W1971156886 @default.
• W3028477515 cites W1977509185 @default.
• W3028477515 cites W1986859702 @default.
• W3028477515 cites W2003199949 @default.
• W3028477515 cites W2016246033 @default.
• W3028477515 cites W2024443399 @default.
• W3028477515 cites W2031302357 @default.
• W3028477515 cites W2034660792 @default.
• W3028477515 cites W2037756744 @default.
• W3028477515 cites W2038252730 @default.
• W3028477515 cites W2040974298 @default.
• W3028477515 cites W2055999577 @default.
• W3028477515 cites W2078978810 @default.
• W3028477515 cites W2089329334 @default.
• W3028477515 cites W2090781292 @default.
• W3028477515 cites W2318289184 @default.
• W3028477515 cites W2324473093 @default.
• W3028477515 cites W2329100179 @default.
• W3028477515 cites W2329393410 @default.
• W3028477515 cites W2339219218 @default.
• W3028477515 cites W2339827976 @default.
• W3028477515 cites W3041047318 @default.
• W3028477515 doi "https://doi.org/10.1097/00126334-200003010-00004" @default.
• W3028477515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10839659" @default.
• W3028477515 hasPublicationYear "2000" @default.
• W3028477515 type Work @default.
• W3028477515 sameAs 3028477515 @default.
• W3028477515 citedByCount "65" @default.
• W3028477515 countsByYear W30284775152012 @default.
• W3028477515 countsByYear W30284775152013 @default.
• W3028477515 countsByYear W30284775152014 @default.
• W3028477515 countsByYear W30284775152016 @default.
• W3028477515 countsByYear W30284775152017 @default.
• W3028477515 countsByYear W30284775152018 @default.
• W3028477515 countsByYear W30284775152021 @default.
• W3028477515 countsByYear W30284775152022 @default.
• W3028477515 countsByYear W30284775152023 @default.
• W3028477515 crossrefType "journal-article" @default.
• W3028477515 hasAuthorship W3028477515A5004101623 @default.
• W3028477515 hasAuthorship W3028477515A5011886669 @default.
• W3028477515 hasAuthorship W3028477515A5018523534 @default.
• W3028477515 hasAuthorship W3028477515A5019250260 @default.
• W3028477515 hasAuthorship W3028477515A5028933821 @default.
• W3028477515 hasAuthorship W3028477515A5036157453 @default.
• W3028477515 hasAuthorship W3028477515A5042498674 @default.
• W3028477515 hasAuthorship W3028477515A5047705773 @default.
• W3028477515 hasAuthorship W3028477515A5048761597 @default.
• W3028477515 hasAuthorship W3028477515A5057786657 @default.
• W3028477515 hasAuthorship W3028477515A5058012553 @default.
• W3028477515 hasAuthorship W3028477515A5075730095 @default.
• W3028477515 hasAuthorship W3028477515A5080933580 @default.
• W3028477515 hasAuthorship W3028477515A5083320502 @default.
• W3028477515 hasAuthorship W3028477515A5089321624 @default.
• W3028477515 hasBestOaLocation W30284775151 @default.
• W3028477515 hasConcept C120665830 @default.
• W3028477515 hasConcept C121332964 @default.
• W3028477515 hasConcept C126322002 @default.
• W3028477515 hasConcept C141071460 @default.
• W3028477515 hasConcept C142462285 @default.
• W3028477515 hasConcept C188816634 @default.
• W3028477515 hasConcept C197934379 @default.
• W3028477515 hasConcept C203014093 @default.
• W3028477515 hasConcept C2776452011 @default.
• W3028477515 hasConcept C2776937687 @default.
• W3028477515 hasConcept C2777210460 @default.
• W3028477515 hasConcept C2778715236 @default.
• W3028477515 hasConcept C2779298103 @default.
• W3028477515 hasConcept C2780727368 @default.
• W3028477515 hasConcept C2781143361 @default.
• W3028477515 hasConcept C2781160516 @default.
• W3028477515 hasConcept C2993143319 @default.
• W3028477515 hasConcept C3013748606 @default.
• W3028477515 hasConcept C61511704 @default.
• W3028477515 hasConcept C71924100 @default.
• W3028477515 hasConcept C90924648 @default.
• W3028477515 hasConceptScore W3028477515C120665830 @default.
• W3028477515 hasConceptScore W3028477515C121332964 @default.
• W3028477515 hasConceptScore W3028477515C126322002 @default.

• next